Tetraphase Pharmaceuticals Inc. (TTPH)
Symbol Info
Listed Symbol TTPH
Name Tetraphase Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $18,904,000
Latest Fiscal EPS $-27.40
Price Info
21 Day Moving Average $4.6704
21 Day EMA $4.697280
50 Day Moving Average $5.2783
50 Day EMA $5.754760
200 Day EMA $17.878750
200 Day Moving Average 15.819810
52 Week High $49.60
52 Week Low $3.36
52 Week Change $-90.614800
Alpha -0.054514
Beta 2.4068
Standard Deviation 0.240047
R2 0.118562
Periods 60
Share Information
10 Day Average Volume 132,150
20 Day Average Volume 144,213
30 Day Average Volume 109,549
50 Day Average Volume 74,420
Outstanding Shares 2,715,826
Float Shares 2,199,800
Percent Float 81.00%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 182
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 1,131,179
Institute Holdings Percent 38.800000
Institute Sold Previous 3 Months 9,222,942
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 13
Insider Holdings Percent 1.00%
Insider Sold Previous 3 Months -
Insiders Shares Owned 516,026
Price Change
7 Day Price Change $0.8199999
7 Day Percent Change 21.81%
21 Day Price Change $-1.1500001
21 Day Percent Change -20.07%
30 Day Price Change $-1.7779999
30 Day Percent Change -27.96%
Month To Date Price Change $-0.74
Month To Date Percent -13.91%
90 Day Price Change $-3.67
90 Day Percent Change -44.48%
Quarter To Date $-0.74
Quarter To Date Percent -13.91%
180 Day Price Change $-16.62
180 Day Percent Change -78.40%
200 Day Price Change $-21.22
200 Day Percent Change -82.25%
Year To Date $-18.02
Year To Date Percent -79.73%
Profile
Description Tetraphase Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is XERAVA (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Details
Issue Type CS
Market Cap $12,438,483
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 2,715,826
CEO Larry Edwards
Employees 119
Last Audit UQ
Classification
CIK 0001373707
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 480 Arsenal Street
Suite 110
Watertown, MA 2472
Website http://www.tphase.com
Facisimile +1 617 926-3557
Telephone +1 617 715-3600
Email
Key Ratios
Profitability
EBIT Margin -1,039.6
EBITDA Margin -1,030.1
Pre-Tax Profit Margin -904.1
Profit Margin Cont -
Gross Margin 88.50
Profit Margin TOT -
Income Statements
Revenue $6,630,000
Revenue Per Share $2.4412
Revenue 3 Years $24.55
Revenue 5 Years $5.43
Valuation Measures
PE Ratio -
Enterprise Value $-22,071,806
Price To Sales 1.876091
Price To Free Cash -0.2
PE High Last 5 Years -
Price To Book 0.3
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 0.3
Financial Strength
Total Debt To Equity 0.8
Int Coverage -31.7
Current Ratio 4.1
Leverage Ratio 2.4
Quick Ratio 3.8
Long Term Debt To Capital 0.41
Assets
Receivables Turnover 0.9
Invoice Turnover 0.60
Assets Turnover -
Management Effectiveness
Return Assets -78.77
Return On Equity -109.46
Return On Capital -74.8
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
TTPH
Tetraphase..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.